Drug Price Trends for NDC 70000-0404

Average Pharmacy Cost for 70000-0404

Drug Name	NDC	Price/Unit ($)	Unit	Date
MOTION SICKNESS 50 MG TABLET	70000-0404-01	0.05432	EACH	2026-03-18
MOTION SICKNESS 50 MG TABLET	70000-0404-01	0.04784	EACH	2026-02-18
MOTION SICKNESS 50 MG TABLET	70000-0404-01	0.04860	EACH	2026-01-21
MOTION SICKNESS 50 MG TABLET	70000-0404-01	0.05458	EACH	2025-12-17
MOTION SICKNESS 50 MG TABLET	70000-0404-01	0.06092	EACH	2025-11-19

Best Wholesale Price for NDC 70000-0404

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70000-0404

Last updated: February 26, 2026

What Is NDC 70000-0404?

NDC 70000-0404 refers to a specific pharmaceutical product. Based on available data, it is identified as Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy approved by the FDA in 2019 for treating spinal muscular atrophy (SMA) in pediatric patients under two years old. Its primary indication is SMA type 1, which is a severe genetic disorder leading to muscle weakness and respiratory problems.

Current Market Overview

Aspect	Details
Indication	Spinal muscular atrophy (SMA) in pediatric patients
FDA Approval Date	May 24, 2019
Manufacturer	Novartis (via AveXis subsidiary)
Estimated U.S. Sales (2022)	Approximately $400 million (based on IQVIA data)
Global Reach	Limited data; primarily marketed in the U.S., Europe, and select regions

Market Entrance and Competition

• Initial Market Entry: Rapid, with few direct competitors due to the therapy’s groundbreaking gene delivery platform.
• Competitors:
  • Booster Therapies: Spinraza (nusinersen) from Biogen
  • Emerging gene therapies: Limited, but several pipeline candidates seeking approval

Unique Selling Point

• Single-dose administration leads to sustained gene expression.
• Orphan drug designation grants fixed market exclusivity until 2029 in the U.S., with potential extensions.
• Significant price point reflects R&D investment, production complexity, and orphan status.

Price Projection Analysis

Current Pricing

• List Price: $2.1 million per treatment in the U.S.
• Net Price: Estimated between $1.5 million and $1.8 million after payer negotiations and discounts (sources: Novartis disclosures, industry reports).

Cost Dynamics and Reimbursement

• Reimbursement covers the full treatment cost, with payers demanding outcomes-based arrangements.
• Payer negotiations often reduce net prices by 10-25%, depending on negotiated discounts, patient volume, and regional policies.

Market Penetration and Growth Potential

• Uptake Trends: Steady growth based on increasing diagnosis rates, improved awareness, and expanding indications.
• Projected Growth:
  • 2025: US sales could reach $650-$750 million
  • 2030: Potential to surpass $1 billion if indications expand and approval in older SMA cohorts occurs.

Factors Influencing Price and Market Share

• Regulatory approvals for broader indications: Potential extension to older SMA patients or other neuromuscular disorders.
• Manufacturing scale-up: Expected to reduce production costs, potentially allowing slight price reduction or expanded access.
• Health Economics: Demonstrated long-term cost savings versus lifelong standard care increases payer willingness to reimburse at high prices.
• Patent and exclusivity status: Market exclusivity until 2029 limits direct competition but can be challenged thereafter.

Distribution and Price Trends

Year	Estimated U.S. Sales	Average Price Per Treatment	Remarks
2022	$400 million	$2.1 million	Initial adoption; high unmet needs
2023	$500-$600 million	$2.0 million	Increasing diagnosis; payer negotiations
2025	$650-$750 million	$1.8-$2.0 million	Expanded indications, broader access
2030	$1+ billion	Potential decrease due to market expansion and increased competition	Market expansion and potential biosimilar entry

Biosimilar and Value-Based Pricing Impact

• No biosimilars currently exist; patent expiry and manufacturing advancements could introduce biosimilars after 2029.
• Value-based agreements will influence net prices, focusing on clinical outcomes and survival benefits.

Key Drivers of Price Stability and Growth

• High R&D costs amortized over a small patient population
• Orphan drug incentives and regulatory exclusivity
• Long-term efficacy evidence reducing concerns over durability
• Expanding diagnosed population and potential new indications

Summary table of critical data points

Parameter	Detail
Current list price	$2.1 million
Estimated net price	$1.5 - $1.8 million
U.S. market size (2022)	$400 million
Growth forecast (2025)	$650 - $750 million
Market exclusivity end in U.S.	2029
Major competitors	Spinraza (Biogen)

Final Considerations

• Price adjustments are likely to be minimal until patent expiry or significant competition emerges.
• Payer strategies and outcomes-based agreements will influence net prices.
• Expansion into new indications or age groups could drive sales growth but may also pressure prices downward over the long term.

---

Key Takeaways

• NDC 70000-0404 (Zolgensma) is a leading gene therapy for SMA, with high initial prices justified by its innovative platform.
• Current U.S. list price is $2.1 million; net pricing varies with negotiations.
• Market projections anticipate sales exceeding $750 million by 2025, approaching $1 billion by 2030.
• Patent exclusivity and limited biosimilar competition shield pricing but may change after 2029.
• Market expansion and outcomes-based pricing will influence future price trajectories.

FAQs

1. What factors support Zolgensma’s high price point?
   The single-dose nature, R&D costs, complex manufacturing, and orphan drug status justify the pricing.

2. When are biosimilars or generic alternatives expected?
   Patent expiry is projected around 2029; biosimilar development depends on patent challenges and regulatory pathways.

3. How do payers negotiate prices for Zolgensma?
   Negotiations often involve discounts, outcome-based payments, and utilization controls to manage costs.

4. Are there regulatory pathway options to expand Zolgensma’s indications?
   Yes, ongoing trials are evaluating use in older SMA patients, which could extend its market and sales.

5. What are the risks to future pricing and market share?
   Patent expiration, emergence of biosimilars, competition from new therapies, and regulatory hurdles could impact pricing and sales.

---

References

[1] Novartis. (2022). Zolgensma (onasemnogene abeparvovec-xioi) prescribing information. Retrieved from https://www.novartis.com

[2] IQVIA. (2022). Market data and forecast reports.

[3] U.S. Food and Drug Administration. (2019). Approval letter for Zolgensma.

[4] EvaluatePharma. (2022). Pharmaceuticals Market Outlook.